Table 2.

Characteristics of the autoantibody positive patients.

Patient ID	Age at onset (years)	Sex	CRP (mg/l)	RF (U/ml)	Anti-CCP(U/ml)	DAS index	Treatment	Detected autoantibody
223	57	male	16	71	749	6.9	Methotrexat, Metilprednizolon, Sulfasalazine	anti-FB IgG
240	52	female			128.47	2.27		anti-C1q IgG
243	75	male		360.9	2403.87	0.84	Tocilizumab	anti-FB IgG
268	67	female				6.59		anti-C1q IgG
274	32	female		40	373	6.54	Methotrexat	anti-FB IgG
277	52	female		120	452.76	5.25	Leflunomide	anti-MBL IgG
282	80	male			497.89	3.09	Certolizumab pegol	anti-FB IgG
288	73	female		249	399	0.91	Tocilizumab	anti-FB IgA
348	73	female			617.34			anti-MBL IgG
547	41	female				3.0	Certolizumab pegol	anti-FB IgG, IgA
557	64	female			290	5.4		anti-C1q IgG
587	45	male			61			anti-C1q IgG

Reference ranges:

RF (rheumatoid factor): >20 U/ml positive.

Anti-CCP (cyclic citrullinated peptide): <20 non-RA, >20 RA.

DAS index (disease activity score): <2.6 remission, 2.6-3.1 low disease activity, 3.1-5.1 moderate disease activity, >5.1 high disease activity.